finance.yahoo.com Regulatory and legal
Akeso (SEHK:9926) Wins China Lung Cancer Approval As Breast Cancer Trial Begins
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Akeso (SEHK:9926) secured regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The ivonescimab combination regimen is positioned as a new standard of care for advanced squamous …